company background image
RGNX

REGENXBIO NasdaqGS:RGNX Stock Report

Last Price

US$26.50

Market Cap

US$1.1b

7D

25.7%

1Y

-34.5%

Updated

26 Jun, 2022

Data

Company Financials +
RGNX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends0/6

RGNX Stock Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.

REGENXBIO Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for REGENXBIO
Historical stock prices
Current Share PriceUS$26.50
52 Week HighUS$46.46
52 Week LowUS$18.69
Beta1.14
1 Month Change31.32%
3 Month Change-17.52%
1 Year Change-34.54%
3 Year Change-48.41%
5 Year Change34.18%
Change since IPO-12.97%

Recent News & Updates

May 12
The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business

The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business

The subdued stock price reaction suggests that REGENXBIO Inc.'s ( NASDAQ:RGNX ) strong earnings didn't offer any...

Shareholder Returns

RGNXUS BiotechsUS Market
7D25.7%10.3%6.6%
1Y-34.5%-24.3%-18.4%

Return vs Industry: RGNX underperformed the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: RGNX underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is RGNX's price volatile compared to industry and market?
RGNX volatility
RGNX Average Weekly Movement10.5%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: RGNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: RGNX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008372Ken Millshttps://www.regenxbio.com

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.

REGENXBIO Fundamentals Summary

How do REGENXBIO's earnings and revenue compare to its market cap?
RGNX fundamental statistics
Market CapUS$1.14b
Earnings (TTM)US$101.26m
Revenue (TTM)US$473.68m

11.3x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGNX income statement (TTM)
RevenueUS$473.68m
Cost of RevenueUS$234.94m
Gross ProfitUS$238.75m
Other ExpensesUS$137.49m
EarningsUS$101.26m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.35
Gross Margin50.40%
Net Profit Margin21.38%
Debt/Equity Ratio0%

How did RGNX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RGNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGNX?

Other financial metrics that can be useful for relative valuation.

RGNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1x
Enterprise Value/EBITDA3.1x
PEG Ratio-1.1x

Price to Earnings Ratio vs Peers

How does RGNX's PE Ratio compare to its peers?

RGNX PE Ratio vs Peers
The above table shows the PE ratio for RGNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average37.1x

Price-To-Earnings vs Peers: RGNX is good value based on its Price-To-Earnings Ratio (11.3x) compared to the peer average (37.1x).


Price to Earnings Ratio vs Industry

How does RGNX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Earnings vs Industry: RGNX is good value based on its Price-To-Earnings Ratio (11.3x) compared to the US Biotechs industry average (15.4x)


Price to Earnings Ratio vs Fair Ratio

What is RGNX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGNX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.3x
Fair PE Ratio18x

Price-To-Earnings vs Fair Ratio: RGNX is good value based on its Price-To-Earnings Ratio (11.3x) compared to the estimated Fair Price-To-Earnings Ratio (18x).


Share Price vs Fair Value

What is the Fair Price of RGNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGNX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: RGNX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Discover undervalued companies

Future Growth

How is REGENXBIO forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-10.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGNX's earnings are forecast to decline over the next 3 years (-10.7% per year).

Earnings vs Market: RGNX's earnings are forecast to decline over the next 3 years (-10.7% per year).

High Growth Earnings: RGNX's earnings are forecast to decline over the next 3 years.

Revenue vs Market: RGNX's revenue (12.4% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: RGNX's revenue (12.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RGNX's Return on Equity is forecast to be low in 3 years time (0.8%).


Discover growth companies

Past Performance

How has REGENXBIO performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-8.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RGNX has high quality earnings.

Growing Profit Margin: RGNX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RGNX has become profitable over the past 5 years, growing earnings by -8.6% per year.

Accelerating Growth: RGNX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RGNX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: RGNX's Return on Equity (14.7%) is considered low.


Discover strong past performing companies

Financial Health

How is REGENXBIO's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: RGNX's short term assets ($446.9M) exceed its short term liabilities ($119.9M).

Long Term Liabilities: RGNX's short term assets ($446.9M) exceed its long term liabilities ($215.8M).


Debt to Equity History and Analysis

Debt Level: RGNX is debt free.

Reducing Debt: RGNX has not had any debt for past 5 years.

Debt Coverage: RGNX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: RGNX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is REGENXBIO current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGNX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RGNX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Ken Mills (46 yo)

13.25yrs

Tenure

US$8,622,940

Compensation

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills was with FOXKISER LLP, most recently as a Partner, from January 200...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD8.62M) is above average for companies of similar size in the US market ($USD4.05M).

Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RGNX's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: RGNX's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

REGENXBIO Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: REGENXBIO Inc.
  • Ticker: RGNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.143b
  • Shares outstanding: 43.13m
  • Website: https://www.regenxbio.com

Number of Employees


Location

  • REGENXBIO Inc.
  • 9804 Medical Center Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.